
Whitehawk Therapeutics, Inc.: shareholders and insiders
Price
$3.07
November 20, 2026Market cap $288M
What Ploutos Investor adds for Whitehawk Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Sep 15, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$2.6M
3 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $2.6M by 3 people
- 2025: no buys, no sales
- 2026: no buys, sold $2.6M by 3 people
- May 14, 2026Anupam DalalDirectorKind
- Apr 16, 2026Scott M. GiacobelloCHIEF FINANCIAL OFFICERKind
- Apr 15, 2026Scott M. GiacobelloCHIEF FINANCIAL OFFICERKind
- Apr 14, 2026Bryan BallKind
- Apr 13, 2026Bryan BallKind
- Apr 10, 2026Bryan BallKind
- Apr 9, 2026Bryan BallKind
- Apr 9, 2026David James LennonCHIEF EXECUTIVE OFFICERKind
- Apr 8, 2026David James LennonCHIEF EXECUTIVE OFFICERKind
- Apr 7, 2026David James LennonCHIEF EXECUTIVE OFFICERKind
- Apr 6, 2026David James LennonCHIEF EXECUTIVE OFFICERKind
- Apr 2, 2026David James LennonCHIEF EXECUTIVE OFFICERKind
- Mar 2, 2026Scott M. GiacobelloCHIEF FINANCIAL OFFICERKind
- Mar 2, 2026Bryan BallKind
- Mar 2, 2026David James LennonCHIEF EXECUTIVE OFFICERKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | Anupam DalalDirector | 1.28M | $3.92 | $5.0M | Form 4 | |
| Apr 16, 2026 | Scott M. GiacobelloCHIEF FINANCIAL OFFICER | 141.6K | $4.13 | $584.8K | Form 4 | |
| Apr 15, 2026 | Scott M. GiacobelloCHIEF FINANCIAL OFFICER | 77.0K | $3.86 | $297.2K | Form 4 | |
| Apr 14, 2026 | Bryan Ball | 92.5K | $3.64 | $336.6K | Form 4 | |
| Apr 13, 2026 | Bryan Ball | 26.4K | $3.46 | $91.3K | Form 4 | |
| Apr 10, 2026 | Bryan Ball | 6,596 | $3.43 | $22.6K | Form 4 | |
| Apr 9, 2026 | Bryan Ball | 50.0K | $3.57 | $178.5K | Form 4 | |
| Apr 9, 2026 | David James LennonCHIEF EXECUTIVE OFFICER | 14.5K | $3.38 | $49.0K | Form 4 | |
| Apr 8, 2026 | David James LennonCHIEF EXECUTIVE OFFICER | 63.9K | $3.40 | $217.4K | Form 4 | |
| Apr 7, 2026 | David James LennonCHIEF EXECUTIVE OFFICER | 94.1K | $3.43 | $322.7K | Form 4 | |
| Apr 6, 2026 | David James LennonCHIEF EXECUTIVE OFFICER | 102.4K | $3.51 | $359.4K | Form 4 | |
| Apr 2, 2026 | David James LennonCHIEF EXECUTIVE OFFICER | 26.9K | $3.48 | $93.5K | Form 4 | |
| Mar 2, 2026 | Scott M. GiacobelloCHIEF FINANCIAL OFFICER | 2,594 | $3.31 | $8.6K | Form 4 | |
| Mar 2, 2026 | Bryan Ball | 1,834 | $3.31 | $6.1K | Form 4 | |
| Mar 2, 2026 | David James LennonCHIEF EXECUTIVE OFFICER | 5,100 | $3.31 | $16.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 15, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by WHWK's officers and directors from 2017 up to November 21, 2025, 9 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 4 more, back to 2017
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Avoro Capital Advisors LLCwith 2 more personsShare of class20.0%
- Suvretta Capital Managementwith 2 more personsShare of class9.99%
- ABG Management Ltd.with 12 more personsShare of class9.40%
- QVT Financial LPShare of class9.37%
- Acuta Capital Partnerswith 2 more personsShare of class9.00%
- OrbiMed Advisors LLCwith 1 more personShare of class7.30%
- Coastlands Capital LPwith 4 more personsShare of class5.98%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLCwith 2 more persons | 20.0% | 18.29M | May 14, 20263 filings since Dec 23, 2024 | 13D/A | |
| Suvretta Capital Managementwith 2 more persons | 9.99% | 4.73M | Mar 11, 2025 | 13G | |
| ABG Management Ltd.with 12 more persons | 9.40% | 5.68M | Aug 14, 20262 filings since Mar 10, 2025 | 13G/A | |
| QVT Financial LP | 9.37% | 2.31M | Feb 14, 2025 | 13G | |
| Acuta Capital Partnerswith 2 more persons | 9.00% | 4.84M | May 18, 20262 filings since Jan 24, 2025 | 13D/A | |
| OrbiMed Advisors LLCwith 1 more person | 7.30% | 3.93M | Aug 14, 20262 filings since May 15, 2025 | 13G/A | |
| Coastlands Capital LPwith 4 more persons | 5.98% | 2.82M | Aug 25, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Avoro Capital Advisors LLC20.0%From the filing of May 14, 2026
On May 12, 2026, the Issuer entered into a Securities Purchase Agreement (the "2026 Securities Purchase Agreement") with Avoro Life Sciences Fund LLC ("Avoro Life") and certain other purchasers named therein (collectively, the "2026 PIPE Investors"). Pursuant to the 2026 Securities Purchase Agreement, the Issuer agreed to sell to Avoro Life an aggregate of 6,377,714 pre-funded warrants (the "Pre-Funded Warrants") to acquire Common Stock at a purchase price of $3.9199 per share (the "2026 PIPE Financing"). The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable, and remain exercisable until exercised in full. Avoro Life may not…
From the filing of May 14, 2026Acuta Capital Partners9.0%From the filing of May 18, 2026
The reporting persons are filing this Schedule 13D because Mr. Dalal is on the Issuer's board of directors. The reporting persons acquired the Stock for investment purposes based on their belief that the Common Stock, when purchased, was undervalued and represented an attractive investment opportunity. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters,…
From the filing of May 18, 2026
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter-68%
- Citadel Advisors (Griffin)In the quarter-50%
- Millennium Mgmt (Englander)In the quarter+16%
- Renaissance TechnologiesIn the quarter+60%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 18.0K | -68% | $100.0K | 0.00% |
| Citadel Advisors (Griffin) | 15.1K | -50% | $100.0K | 0.00% |
| Millennium Mgmt (Englander) | 442.9K | +16% | $1.7M | 0.00% |
| Renaissance Technologies | 663.9K | +60% | $2.5M | 0.00% |
| AQR Capital | 13.5K | $100.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 2.79% of its shares outstanding were held short, -3.3% since the report before.
- Shares held short
- 2.62M
- 2.79%
- Since the report before2.71M on Sep 30, 2026
- -3.3%
- 7.4
- 354.2K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 80%
- Report date
- Oct 15, 2026
- Shares held short
- Mar 31, 2025: Shares held short 1.17M
- Apr 15, 2025: Shares held short 1.14M
- Apr 30, 2025: Shares held short 213.8K
- May 15, 2025: Shares held short 186.2K
- May 30, 2025: Shares held short 173.3K
- Jun 13, 2025: Shares held short 285.8K
- Jun 30, 2025: Shares held short 618.3K
- Jul 15, 2025: Shares held short 381.9K
- Jul 31, 2025: Shares held short 362.1K
- Aug 15, 2025: Shares held short 294.5K
- Aug 29, 2025: Shares held short 242.7K
- Sep 15, 2025: Shares held short 258.1K
- Sep 30, 2025: Shares held short 233.0K
- Oct 15, 2025: Shares held short 208.5K
- Oct 31, 2025: Shares held short 1.03M
- Nov 14, 2025: Shares held short 978.2K
- Nov 28, 2025: Shares held short 649.2K
- Dec 15, 2025: Shares held short 760.6K
- Dec 31, 2025: Shares held short 735.6K
- Jan 15, 2026: Shares held short 780.8K
- Jan 30, 2026: Shares held short 847.4K
- Feb 13, 2026: Shares held short 777.2K
- Feb 27, 2026: Shares held short 780.9K
- Mar 13, 2026: Shares held short 722.2K
- Mar 31, 2026: Shares held short 693.9K
- Apr 15, 2026: Shares held short 780.1K
- Apr 30, 2026: Shares held short 824.7K
- May 15, 2026: Shares held short 855.0K
- May 29, 2026: Shares held short 843.7K
- Jun 15, 2026: Shares held short 1.18M
- Jun 30, 2026: Shares held short 2.83M
- Jul 15, 2026: Shares held short 4.18M
- Jul 31, 2026: Shares held short 4.43M
- Aug 14, 2026: Shares held short 5.03M
- Aug 31, 2026: Shares held short 2.98M
- Sep 15, 2026: Shares held short 2.73M
- Sep 30, 2026: Shares held short 2.71M
- Oct 15, 2026: Shares held short 2.62M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading43.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 43.1% of the shares in the reported trades were short sales, against 52.3% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 43.1%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 52.3%
- Change
- -9.2 pts
- Short sales a dayon average, of 196.0K shares
- 84.5K
- More than atof 3,666 US-listed companies, same days
- 27%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 42.9%
- Oct 15, 2026: Short sales 84.3%
- Oct 16, 2026: Short sales 71.7%
- Oct 19, 2026: Short sales 65.4%
- Oct 20, 2026: Short sales 33.7%
- Oct 21, 2026: Short sales 63%
- Oct 22, 2026: Short sales 45.7%
- Oct 23, 2026: Short sales 71.4%
- Oct 26, 2026: Short sales 63.7%
- Oct 27, 2026: Short sales 26.5%
- Oct 28, 2026: Short sales 34.1%
- Oct 29, 2026: Short sales 43.5%
- Oct 30, 2026: Short sales 72.6%
- Nov 2, 2026: Short sales 43.7%
- Nov 3, 2026: Short sales 30.8%
- Nov 4, 2026: Short sales 25.5%
- Nov 5, 2026: Short sales 55.7%
- Nov 6, 2026: Short sales 37%
- Nov 9, 2026: Short sales 27.2%
- Nov 10, 2026: Short sales 47.5%
- Nov 11, 2026: Short sales 19.8%
- Nov 12, 2026: Short sales 80.3%
- Nov 13, 2026: Short sales 57.7%
- Nov 16, 2026: Short sales 69.7%
- Nov 17, 2026: Short sales 66.9%
- Nov 18, 2026: Short sales 59%
- Nov 19, 2026: Short sales 71.5%
- Nov 20, 2026: Short sales 66.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Anupam DalalDirectorDirectly4.69M
- Neil DesaiEXECUTIVE CHAIRMANDirectly–
- David James LennonCHIEF EXECUTIVE OFFICERDirectly518.6K
- Bryan BallSee remarksDirectly397.1K
- Scott M. GiacobelloCHIEF FINANCIAL OFFICERDirectly295.2K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Anupam DalalDirector | 4.69M | – | May 14, 2026 | Form 4 |
| Neil DesaiEXECUTIVE CHAIRMAN | – | 1.17M | Sep 3, 2024 | Form 4 |
| David James LennonCHIEF EXECUTIVE OFFICER | 518.6K | – | Apr 9, 2026 | Form 4 |
| Bryan BallSee remarks | 397.1K | – | Apr 14, 2026 | Form 4 |
| Scott M. GiacobelloCHIEF FINANCIAL OFFICER | 295.2K | – | Apr 16, 2026 | Form 4 |
A lower bound: it counts only the 5 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.03%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.00%
| ETF | Weight in the fund | Holdings as of |
|---|---|---|
| IWCiShares Micro-Cap ETF | 0.03% | Jun 30, 2026 |
| IWNiShares Russell 2000 Value ETF | 0.01% | Jun 30, 2026 |
| IWMiShares Russell 2000 ETF | 0.00% | Jun 30, 2026 |
3 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 41
- Q4 2025: Managers 48
- Q1 2026: Managers 64
- Q2 2026: Managers 78
Institutional investors by quarter
The fund managers holding WHWK, quarter by quarter, from Q3 2021 to Q2 2025, 16 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 78 managers held 43.24M shares, worth $198M. During the quarter 28 opened a position, 15 closed one, 28 added and 10 trimmed.
The largest holders, Q2 2026
- Yu FanIn the quarter+135%
- Acuta Capital PartnersIn the quarter+37%
- QVT FinancialIn the quarter
- Montanova CapitalIn the quarter+16%
- Orbimed AdvisorsIn the quarter-5.6%
- Avoro Capital AdvisorsIn the quarter
- SirenIn the quarter+12%
- KVP Capital AdvisorsIn the quarter
- BlackRockIn the quarter+447%
- Vanguard Capital ManagementIn the quarter+5.5%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Yu Fan | 4.86M | +135% | $22M |
| Acuta Capital Partners | 4.69M | +37% | $21M |
| QVT Financial | 4.62M | $21M | |
| Montanova Capital | 4.30M | +16% | $20M |
| Orbimed Advisors | 3.93M | -5.6% | $18M |
| Avoro Capital Advisors | 2.85M | $13M | |
| Siren | 2.34M | +12% | $11M |
| KVP Capital Advisors | 2.17M | $9.9M | |
| BlackRock | 1.92M | +447% | $8.8M |
| Vanguard Capital Management | 1.39M | +5.5% | $6.4M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Whitehawk Therapeutics's filings show?
Who buys and sells is one part of Whitehawk Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have WHWK's insiders bought or sold?
From Jun 15, 2026 to Sep 15, 2026 Whitehawk Therapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold WHWK?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $2.5M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.